Tradestie Institutional Equity Comparison Engine

ABVC vs AQB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABVC Overall Edge

ABVC Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin, Options & Structure while AQB counters with relative strength in Momentum & Technical. Fundamentally, ABVC trades at N/M Forward P/E with 0.0% operating margin (+104.5% YoY revenue) versus AQB at N/M Forward P/E and 0.0% operating margin (-93.5% YoY). In options structure, ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AQB sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABVC N/M vs AQB N/M Fwd P/E
Growth & Margin Winner ABVC
Op Margin 0.0% vs 0.0% ยท YoY +104.5% vs -93.5%
Momentum & Technical Winner AQB
1Y -67.8% vs -23.6% ยท 52W Pos 10% vs 11%
Options & Structure Winner ABVC
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+0.0% 1D
Market Cap $24.8M
1M Return +3.3%
1Y Return -67.81%
Forward P/E N/M
Unified AI Score
34.2 / 100 SELL
Tech 15.0 Fund 40.0 Flow 50.0 Mom 40.0
AQB NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap $9.7M
1M Return -21.37%
1Y Return -23.57%
Forward P/E N/M
Unified AI Score
44.6 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABVC -67.81% AQB -23.57% Spread: +44.24 pp (AQB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABVC TTM Op. Margin: 0.0% AQB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs AQB. Trailing 12-month operating profitability (ABVC 0.0% vs AQB 0.0%) and valuation multiples (ABVC N/M vs AQB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABVC (4) vs AQB (2)
Institutional Metric ABVC AQB Criterion Row Winner
Market Capitalization Scale $24.8M $9.7M Larger Scale ABVC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +104.5% -93.5% Higher Growth ABVC
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -52.7% -68.9% Higher ROE ABVC
52-Week Range Position Momentum 10% ($1โ€“$3) 11% ($1โ€“$2) Stronger Trend AQB
Beta / 30D Volatility Risk Regime 1.34ฮฒ ยท 53% Vol 0.93ฮฒ ยท 117% Vol Lower Realized Risk ABVC
Unified Institutional Score Composite Signal 34.2 / 100 (SELL) 44.6 / 100 (HOLD) Higher Composite AQB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABVC vs AQB Buy Guide
ABVC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABVC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AQB BREAKDOWN
69d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AQB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABVC nor AQB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.